Clovis Oncology Inc. Stock
Price
Target price
€0.68
€0.68
-4.040%
-
-4.040%
?
20.05.22 / Tradegate
WKN: A1JPJY / Symbol: CLVS / Name: Clovis Oncology / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Clovis Oncology Inc. Stock
Heavy losses for Clovis Oncology Inc. today as the stock fell by €0.000 (-4.040%).
Currently there is a rather positive sentiment for Clovis Oncology Inc. with 3 Buy predictions and 1 Sell predictions.
For the coming years our community has positive and negative things to say abot the Clovis Oncology Inc. stock. Criterium "Shareholder structure" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Clovis Oncology Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Clovis Oncology Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Clovis Oncology Inc. | -4.040% | -9.860% | -66.189% | -84.301% | -71.810% | -95.482% | -98.555% |
| Epizyme Inc. | 1.410% | -2.400% | -29.784% | -93.131% | -78.243% | - | - |
| Pieris Pharmaceuticals Inc | -0.140% | 4.332% | -40.580% | 12.709% | -42.353% | - | - |
| Capricor Therapeutics Inc | 1.220% | 18.766% | 12.931% | 4.088% | 27.308% | - | - |
Comments
News
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2022, and provided an update on the Company’s clinical development programs and regulatory and
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that seven abstracts from the company’s pipeline, including late-breaking data from the ATHENA-MONO Phase 3 clinical trial evaluating Rubraca